Now showing items 1-1 of 1

    • Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial. 

      Judson, I; Morden, JP; Kilburn, L; Leahy, M; Benson, C; Bhadri, V; Campbell-Hewson, Q; Cubedo, R; Dangoor, A; Fox, L; Hennig, I; Jarman, K; Joubert, W; Kernaghan, S; López Pousa, A; McNeil, C; Seddon, B; Snowdon, C; Tattersall, M; Toms, C; Martinez Trufero, J; Bliss, JM (2019-07)
      Background Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is unresponsive to chemotherapy. Cediranib, a tyrosine-kinase inhibitor, has shown substantial activity in ASPS in non-randomised studies. The ...